Southern Shuanglin Bio-Pharmacy to unlock restricted shares

Southern Shuanglin Bio-Pharmacy (SZSE:000403) announced the upcoming release of 40,333,702 restricted shares, constituting 5.52% of its total share capital, for trading on February 26, 2025. This release stems from a share issuance and asset purchase transaction. Guotai Junan Securities, the independent financial advisor, has reviewed the matter and confirmed compliance with relevant regulations. The unlocked shares involve seven shareholders, including institutional investors like Lanxiang Biology and Tongzhi Cheng Technology, as well as individual shareholders. The company confirmed that the shareholders involved have fulfilled their commitments and there were no instances of non-operating fund occupation or irregular guarantees. The unlocking will increase the company's unrestricted shares to 99.43% of the total share capital. The decision was based on the completion of profit targets in 2023, with the company's net profit exceeding the target by 128.93%.